Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.
Better Therapeutics shares are traded on the NASDAQ under the ticker symbol “BTTX”.
Better Therapeutics' fiscal year end is December 31.
Better Therapeutics began trading on October 29, 2021 under the ticker symbol BTTX as a result of a merger with a special purpose acquisition company (SPAC).
Our CUSIP number is 62402D105
Our transfer agent is Continental Stock Transfer & Trust Company
Please email IR@bettertx.com